Cambridge, UK, 02 October 2023: Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of Read More
Tags :Astellas Venture Management
PhoreMost closes £33M ($46M) Series B financing Funding to support progression of PLK1 program, for treatment of brain cancer, into the clinic within 18 months Company is advancing its pipeline of novel therapies for oncology Read More